Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FDG-PET Variability for Biology-Guided SBRT Planning
NCT03493789Phase 1Completed
- Sponsor
- Emory University
- Start
- Apr 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fludeoxyglucose f 18 in non-small cell lung cancer (NSCLC), lung cancer and cancer, sponsored by Emory University. Primary endpoints: Change in metabolic tumor volumes measuring inter-fraction variability of fludeoxyglucose F-18-PET activity of thoracic SBRT target volumes at 6 weeks and Change in total lesion glycolysis values measuring inter-fraction variability of fludeoxyglucose F-18-PET activity of thoracic SBRT target volumes at 6 weeks. Started Apr 2018; status: completed.
02
Drugs
fludeoxyglucose f 18
03
Conditions
non-small cell lung cancer (NSCLC)lung cancercancer
Beyond the preview
Go deeper on NCT03493789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03493789.